Publications by authors named "Yoshihiro Inamoto"

Claim this Profile
A
Advances in treatment of chronic graft-versus-host disease.
Takanobu Morishita, Yoshihiro Inamoto

Int J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.
Akinao Okamoto, Masahiro Yoshida, Senji Kasahara, Takahide Ara, Kazutaka Ozeki, Yoshihiro Inamoto

Front Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study.
Koji Kato, Yoshihiro Inamoto, Toshiro Kawakita, Yasushi Onishi, Ken-Ichi Matsuoka

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir.
Toshihisa Nakashima, Azusa Kawasaki, Yoshihiro Inamoto, Ayumu Ito, Takahiro Fukuda

Jpn J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study.
Ao Ito, Kaori Ito, Chisako Iriyama, Naoe Goto, Yoshihiro Inamoto

Cureus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.
Yu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, Hideki Nakasone, Marcio A Diniz

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors.
Yoshimitsu Shimomura, Sho Komukai, Tetsuhisa Kitamura, Kazuki Yoshimura, Yoshihiro Inamoto

Br J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.
Junya Makiyama, Nobuhiro Ohno, Koji Jimbo, Toyotaka Kawamata, Kazuaki Yokoyama, Yoshihiro Inamoto

Int J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease.
Yoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, Asako Usui, Wataru Takeda

Int J Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic cell transplantation.
Masatomo Kuno, Takashi Tanaka, Akiko Miyagi Maeshima, Hiroyuki Takamaru, Yasuo Kakugawa, Yoshihiro Inamoto

Bone Marrow Transplant· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.
Pashna N Munshi, Rebecca L Olin, Sarah Wall, Shannon R McCurdy, Taha Al-Juhaishi, Yoshihiro Inamoto

Transplant Cell Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis.
Toshihisa Nakashima, Yoshihiro Inamoto, Ayumu Ito, Sung-Won Kim, Takahiro Fukuda

Int J Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail, Yoshihiro Inamoto

Transplant Cell Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease.
Takanobu Morishita, Paul J Martin, Yoshihiro Inamoto

Cells· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Overview].
Yoshihiro Inamoto

Rinsho Ketsueki· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.
Yoshihiro Inamoto, Koji Kato, Toshiro Kawakita, Yasushi Onishi, Ken-Ichi Matsuoka

Am J Hematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study.
Justine Kahn, Ruta Brazauskas, Stephanie Bo-Subait, David Buchbinder, Betty K Hamilton, Yoshihiro Inamoto

Lancet Child Adolesc Health· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data.
Yachiyo Kuwatsuka, Hidemi Ito, Ken Tabuchi, Takaaki Konuma, Naoyuki Uchida, Yoshihiro Inamoto

Bone Marrow Transplant· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.
Junya Kanda, Takaya Mitsuyoshi, Masatoshi Sakurai, Hisakazu Nishimori, Makoto Murata, Yoshihiro Inamoto

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy.
Hamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, Pashna N Munshi, Yoshihiro Inamoto

Transplant Cell Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
Tania Jain, Noel Estrada-Merly, M Queralt Salas, Soyoung Kim, Jakob DeVos, Yoshihiro Inamoto

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between acute and chronic graft-versus-host disease.
Masaharu Tamaki, Yu Akahoshi, Yoshihiro Inamoto, Kaoru Morita, Naoyuki Uchida

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Takanori Teshima, Yasushi Onishi, Koji Kato, Shuichi Taniguchi, Koichi Miyamura, Yoshihiro Inamoto

Int J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric profiles with CD7 and CADM1 in CD4+ T cells are promising indicators for prognosis of aggressive ATL.
Koji Jimbo, Toyotaka Kawamata, Yoshihiro Inamoto, Ayumu Ito, Kazuaki Yokoyama

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Adenovirus disease after hematopoietic cell transplantation].
Yoshihiro Inamoto

Rinsho Ketsueki· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis